Compare Erasca Inc. Common Stock (ERAS) vs Westinghouse Air Brake Technologies Corporation Common Stock (WAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Erasca Inc. Common Stock vs Westinghouse Air Brake Technologies Corporation Common Stock — how do they compare? Erasca Inc. Common Stock trades at $14.6 (market cap $5.17B), while Westinghouse Air Brake Technologies Corporation Common Stock trades at $286.02 (market cap $48.39B). The key difference: Westinghouse Air Brake Technologies Corporation Common Stock is far larger — about 9.4× Erasca Inc. Common Stock's market cap, and Westinghouse Air Brake Technologies Corporation Common Stock pays a 0.43% dividend while Erasca Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Erasca Inc. Common Stock for 1 Days and Westinghouse Air Brake Technologies Corporation Common Stock for 0 Days on average.
| ERAS | WAB | |
|---|---|---|
Market Cap | $5.17B | $48.39B |
Volume | 5,313,379 | 960,464 |
Sector | Health | Industrials |
52-Week High | $22.47 | $305.79 |
52-Week Low | $2.20 | $193.43 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $4.95B | $54.30B |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ERAS trades at $14.78, down 4.4% today, with a bullish technical signal from moving averages and a consensus analyst price target of $22.50. The company is a clinical-stage oncology firm with no revenue, reporting a net loss of $124.55 million in 2025, but holds significant liquidity and has three potential registration-enabling trials ahead. Recent news highlights FDA Fast Track designation for its lead candidate ERAS-0015.
The outlook is speculative, driven by clinical trial progress; upside exists if trials succeed, but high cash burn and shareholder investigations pose substantial risks. Investment hinges on binary outcomes from drug development, making it suitable only for risk-tolerant investors focused on biotech.
Wabtec (WAB) trades at $286.51, up 0.26% today, with a neutral technical signal. The company shows strong fundamentals, with Q2 2026 EPS of $2.76 beating estimates and revenue growth to $12.0B projected for 2026. A $700M+ African rail services deal and raised full-year guidance highlight positive business momentum. Key support rests at $284, with resistance at $288.
The outlook is positive, driven by earnings beats, margin expansion, and a robust backlog. Risks include premium valuation (P/E 38.56) and investing cash outflows. Analyst consensus is bullish with a $326.50 price target, suggesting ~14% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Erasca Inc. Common Stock
Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →About Westinghouse Air Brake Technologies Corporation Common Stock
Westinghouse Air Brake Technologies Corporation, known as Wabtec, provides equipment, systems, and services for the freight rail and passenger transit industries. Its Freight segment supplies locomotives, braking systems, and signaling technology, while its Transit segment supports passenger rail systems worldwide.
Read more on WAB →
